Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

Osteoarthritis is a highly prevalent joint disease that leads to cartilage breakdown, pain and disability, yet there are ...

The new method is designed to focus specifically on pain-related signals, without interfering with normal activity in other ...

For those born with certain types of congenital deafness, the cochlear implant has been a positive and enabling technology.

Sarepta Therapeutics Inc. fell Monday after reporting its embattled gene therapy is expected to miss fourth-quarter sales ...